Do you have Eosinophilic Esophagitis? Consider joining a study of a medication.

eosinophilic esophagitis

Now Recruiting Study Participants

 

Qualified participants:

  • Receive study-related care at no cost from a local doctor
  • No need for health insurance
See If You Qualify

Study Details

  • We are participating in a national study of a medication called Dupilumab in patients with Eosinophilic Esophagitis (EoE).
  • Eosinophilic Esophagitis or Eoe is an allergic inflammatory disease that damages the lining of the esophagus leading to difficulty swallowing.
  • Dupilumab is a medication made by Regeneron Pharmaceuticals.
  • The safety and efficacy of Dupilumab for use in patients with Eosinophilic Esophagitis is being evaluated in this study. 
  • Dupixent is FDA approved for the treatment of moderate to severe atopic dermatitis, moderate to severe asthma, and chronic rhinosinusitis with nasal polyposis.
  • It is not FDA approved for the treatment of Eosinophilic Esophagitis.

See If You Qualify